Stoke Therapeutics Hits New 52-Week High of $39.81, Up 146.41%

Stoke Therapeutics, Inc. has reached a significant milestone by hitting a new 52-week high of USD 39.81 on March 2, 2026. This achievement underscores the company's strong performance in the pharmaceuticals and biotechnology sector, where it has demonstrated a remarkable one-year performance of 146.41%, significantly outpacing the S&P 500's 17.36% return. With a market capitalization of USD 1,959 million, Stoke Therapeutics is classified as a small-cap company. The stock's price-to-earnings (P/E) ratio stands at 36.00, reflecting investor sentiment and the company's growth potential. Additionally, the company maintains a return on equity of 13.17%, indicating effective management of shareholder equity. Stoke Therapeutics has not distributed dividends, as evidenced by a dividend yield of 0.00%. The company's debt-to-equity ratio is reported at -0.80, suggesting a strong balance sheet. The price-to-book ratio of 6.36 further highlights the stock's valuation in relation to its book value. Overall, Stoke Therapeutics' recent performance and financial metrics illustrate its position within the competitive landscape of the pharmaceuticals and biotechnology industry.